Management of glioblastoma multiforme with special reference to recurrence

被引:42
|
作者
Durmaz, R [1 ]
Erken, S [1 ]
Arslantas, A [1 ]
Atasoy, MA [1 ]
Bal, C [1 ]
Tel, E [1 ]
机构
[1] OSMANGAZI UNIV,FAC MED,DEPT BIOSTAT,TR-26480 ESKISEHIR,TURKEY
关键词
glioblastoma multiforme; surgery; reoperation; radiotherapy; survival;
D O I
10.1016/S0303-8467(97)00014-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Between 1985 and 1995, 46 patients underwent craniotomy for glioblastoma multiforme. The mean age was 47, varying from 9 to 71 years. The influence of such prognostic factors as age, preoperative Karnofsky score, extent of resection, tumour site, tumour size, radiotherapy, reoperation as well as initial symptoms upon survival were studied. Of these, gross complete removal, radiotherapy, preoperative Karnofsky score, and reoperation were shown to be statistically significant to the survival time according to logrank and univariate tests. However, age, preoperative Karnofsky score, tumour size and temporal localisation remained as significant factors in multivariate analysis. The overall median survival was 53 weeks, with no patients surviving more than 3 years. Of the patients, 41% survived over a year and 8.6% lived over two years. Twenty-six patients developed a recurrent mass after an interval of 32 weeks. The median interval time from operation to recurrence was longer in those patients who underwent gross removal than in those who had a subtotal resection, 28.2 against 20 weeks (P < 0.05). Of patients who had a recurrent mass, 16 were reoperated on, with a subsequent median survival time of 26.5 weeks. Our experience suggests that the survival of patients with glioblastoma depends on many factors, including radical surgery as an initial step. In addition, the gross total removal of the tumour also delays the development of recurrence. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:117 / 123
页数:7
相关论文
共 50 条
  • [31] Glioblastoma Multiforme
    Sheehan, Jonas M.
    Cavaliere, Robert
    Farace, Elena
    Bredel, Markus
    Burri, Stuart H.
    [J]. NEUROLOGY RESEARCH INTERNATIONAL, 2012, 2012
  • [32] Glioblastoma multiforme
    Newton, Herbert B.
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2008, 10 (04) : 285 - 294
  • [33] Glioblastoma multiforme
    Herbert B. Newton
    [J]. Current Treatment Options in Neurology, 2008, 10 : 285 - 294
  • [34] Standards of care and novel approaches in the management of glioblastoma multiforme
    Andreas F.Hottinger
    Roger Stupp
    Krisztian Homicsko
    [J]. 癌症, 2014, 33 (01) : 32 - 39
  • [35] Glioblastoma multiforme
    Welch, Mary
    Lai, Rose
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2009, 11 (04) : 297 - 305
  • [36] Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
    Camilo E. Fadul
    Patrick Y. Wen
    Lyndon Kim
    Jeffrey J. Olson
    [J]. Journal of Neuro-Oncology, 2008, 89 : 339 - 357
  • [37] Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme
    Greish, Khaled
    Jasim, Anfal
    Parayath, Neha
    Abdelghany, Sara
    Alkhateeb, Ali
    Taurin, Sebastien
    Nehoff, Hayley
    [J]. JOURNAL OF DRUG TARGETING, 2018, 26 (08) : 692 - 708
  • [38] Role of a Combination of Seven Micronutrients in the Management of Glioblastoma Multiforme
    Rooprai, H. K.
    Ashkan, K.
    Brazil, L.
    Selway, R. P.
    Lodhi, R.
    Aitchison, K. J.
    Gullan, R. W.
    Beaney, R.
    [J]. CLINICAL ONCOLOGY, 2015, 27 (06) : 370 - 371
  • [39] Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
    Fadul, Camilo E.
    Wen, Patrick Y.
    Kim, Lyndon
    Olson, Jeffrey J.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2008, 89 (03) : 339 - 357
  • [40] Double balloon GliaSite in the management of recurrent glioblastoma multiforme
    Payne, JT
    St Clair, WH
    Given, CA
    Young, B
    Meigooni, A
    [J]. SOUTHERN MEDICAL JOURNAL, 2005, 98 (09) : 957 - 958